(Q54281304)

English

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Konstanze Döhner

13

object named as

Konstanze Döhner

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

Hartmut Döhner

15

object named as

Hartmut Döhner

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

Gudrun Göhring

9

object named as

Gudrun Göhring

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

author name string

Walter Fiedler

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Sabine Kayser

2

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Maxim Kebenko

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Melanie Janning

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Jürgen Krauter

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Marcus Schittenhelm

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Katharina Götze

7

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Daniela Weber

8

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Veronica Teleanu

10

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Felicitas Thol

11

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Michael Heuser

12

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Arnold Ganser

14

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Richard F Schlenk

16

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

language of work or name

0 references

publication date

29 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

169

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

694-700

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Functional heterogeneity of genetically defined subclones in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

The evolving molecular genetic landscape in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13353

21 January 2018

Identifiers

10.1111/BJH.13353

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54281304&oldid=1404513736"